Rani Therapeutics Holdings, Inc. (RANI) stock
RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3039% above fair value
$0.54+0.01 (+2.66%)
Close on Nov 16, 2026Market cap $75.32MP/E –Yield –
Rani Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Rani Therapeutics's total debt was $0 at Dec 31, 2025. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $29.38M in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $24.61M | -16.2% |
| FY2023 | Dec 31, 2023 | $29.38M | +0.8% |
| FY2022 | Dec 31, 2022 | $29.15M | – |
| FY2021 | Dec 31, 2021 | $0 | -100.0% |
| FY2020 | Dec 31, 2020 | $3.77M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $13.54M | -52.2% |
| Q2 FY2025 | Jun 30, 2025 | $17.23M | -41.6% |
| Q1 FY2025 | Mar 31, 2025 | $20.92M | -28.9% |
| Q4 FY2024 | Dec 31, 2024 | $24.61M | -16.2% |
| Q3 FY2024 | Sep 30, 2024 | $28.31M | -3.5% |
| Q2 FY2024 | Jun 30, 2024 | $29.50M | +0.8% |
| Q1 FY2024 | Mar 31, 2024 | $29.44M | +0.8% |
| Q4 FY2023 | Dec 31, 2023 | $29.38M | +0.8% |
| Q3 FY2023 | Sep 30, 2023 | $29.32M | +108.1% |
| Q2 FY2023 | Jun 30, 2023 | $29.27M | – |
| Q1 FY2023 | Mar 31, 2023 | $29.21M | – |
| Q4 FY2022 | Dec 31, 2022 | $29.15M | +650.5% |
| Q3 FY2022 | Sep 30, 2022 | $14.09M | +273.7% |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
| Q3 FY2021 | Sep 30, 2021 | $0 | – |
| Q2 FY2021 | Jun 30, 2021 | $3.88M | – |
| Q4 FY2020 | Dec 31, 2020 | $3.77M | – |
See a number that looks wrong?